Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions Journal Article


Authors: Lancaster, J. M.; Bethan Powell, C.; Kauff, N. D.; Cass, I.; Chen, L. M.; Lu, K. H.; Mutch, D. G.; Berchuck, A.; Karlan, B. Y.; Herzog, T. J.
Article Title: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions
Abstract: Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast/Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk ovarian cancer. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2 or MSH6, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40-60% lifetime risk of both endometrial and colorectal cancer as well as a 9-12% lifetime risk of ovarian cancer. Genetic risk assessment enables physicians to provide individualized evaluation of the likelihood of having one of these gynecologic cancer predisposition syndromes, as well the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Hereditary cancer risk assessment is a process that includes assessment of risk, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome. © 2007 Elsevier Inc. All rights reserved.
Keywords: gene mutation; cancer risk; endometrial neoplasms; endometrium cancer; counseling; colorectal cancer; ovarian neoplasms; cancer susceptibility; genetic predisposition to disease; ovary cancer; breast cancer; risk factors; patient education; cancer screening; editorial; breast neoplasms; brca1 protein; brca2 protein; risk assessment; genital neoplasms, female; cancer genetics; oncogene; genes, brca1; genes, brca2; mismatch repair; dna mismatch repair; medical society; familial cancer; genetic screening; population surveillance; gynecologic cancer; protein mlh1; protein msh2; protein msh6; colorectal neoplasms, hereditary nonpolyposis; patient counseling; germ-line mutation
Journal Title: Gynecologic Oncology
Volume: 107
Issue: 2
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2007-11-01
Start Page: 159
End Page: 162
Language: English
DOI: 10.1016/j.ygyno.2007.09.031
PUBMED: 17950381
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 41" - "Export Date: 17 November 2011" - "CODEN: GYNOA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Noah Kauff
    128 Kauff